LOSS OF THE TUMOR SUPPRESSOR, TP53, ENHANCES THE ANDROGEN RECEPTOR MEDIATED ONCOGENIC TRANSFORMATION AND TUMOR DEVELOPMENT IN THE MOUSE PROSTATE

[1]  Chris J. Stubben,et al.  The Lineage‐Defining Transcription Factors SOX2 and NKX2–1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment , 2018, Immunity.

[2]  Joshua M. Stuart,et al.  Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Henry W. Long,et al.  A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer , 2018, Cell.

[4]  Joshua M. Stuart,et al.  Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer , 2018, Cell.

[5]  Menggang Yu,et al.  Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy , 2017, JAMA oncology.

[6]  M. Rubin,et al.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.

[7]  E. Klein,et al.  Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. , 2016, Cancer research.

[8]  Måns Magnusson,et al.  MultiQC: summarize analysis results for multiple tools and samples in a single report , 2016, Bioinform..

[9]  P. V. van Diest,et al.  Cytokeratin and protein expression patterns in squamous cell carcinoma of the oral cavity provide evidence for two distinct pathogenetic pathways , 2016, Oncology letters.

[10]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[11]  Joshua M. Stuart,et al.  A basal stem cell signature identifies aggressive prostate cancer phenotypes , 2015, Proceedings of the National Academy of Sciences.

[12]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[13]  M. Tupone,et al.  SNAI2/Slug gene is silenced in prostate cancer and regulates neuroendocrine differentiation, metastasis-suppressor and pluripotency gene expression , 2015, Oncotarget.

[14]  R. Luong,et al.  Androgen Signaling Is a Confounding Factor for β-catenin-mediated Prostate Tumorigenesis , 2015, Oncogene.

[15]  Samantha A. Morris,et al.  CellNet: Network Biology Applied to Stem Cell Engineering , 2014, Cell.

[16]  D. Hwang,et al.  Identification of key regulators for the migration and invasion of rheumatoid synoviocytes through a systems approach , 2013, Proceedings of the National Academy of Sciences.

[17]  Aaron R Cooper,et al.  Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells , 2013, Proceedings of the National Academy of Sciences.

[18]  D. Zheng,et al.  ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss , 2013, Nature Medicine.

[19]  Gerald C. Chu,et al.  Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. , 2013, Cancer research.

[20]  R. Luong,et al.  Conditional Deletion of the Pten Gene in the Mouse Prostate Induces Prostatic Intraepithelial Neoplasms at Early Ages but a Slow Progression to Prostate Tumors , 2013, PloS one.

[21]  K. Hochedlinger,et al.  The sox family of transcription factors: versatile regulators of stem and progenitor cell fate. , 2013, Cell stem cell.

[22]  Yuzhuo Wang,et al.  Deletion of Leucine Zipper Tumor Suppressor 2 (Lzts2) Increases Susceptibility to Tumor Development* , 2012, The Journal of Biological Chemistry.

[23]  Hui Zhou,et al.  ChIPBase: a database for decoding the transcriptional regulation of long non-coding RNA and microRNA genes from ChIP-Seq data , 2012, Nucleic Acids Res..

[24]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[25]  Scott C. Williams,et al.  Radioimmunotherapy of Non-Hodgkin’s Lymphoma: From the ‘Magic Bullets’ to ‘Radioactive Magic Bullets’ , 2011, The Yale journal of biology and medicine.

[26]  J. McKenney,et al.  Conditional Expression of the Androgen Receptor Induces Oncogenic Transformation of the Mouse Prostate* , 2011, The Journal of Biological Chemistry.

[27]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[28]  Li Chen,et al.  hmChIP: a database and web server for exploring publicly available human and mouse ChIP-seq and ChIP-chip data , 2011, Bioinform..

[29]  Avi Ma'ayan,et al.  ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments , 2010, Bioinform..

[30]  Yuchen Bai,et al.  Research Resource: The androgen receptor modulates expression of genes with critical roles in muscle development and function. , 2010, Molecular endocrinology.

[31]  M. Robinson,et al.  A scaling normalization method for differential expression analysis of RNA-seq data , 2010, Genome Biology.

[32]  J. Mirosevich,et al.  Prostate epithelial cell fate. , 2008, Differentiation; research in biological diversity.

[33]  R. Shamir,et al.  Transcription factor and microRNA motif discovery: the Amadeus platform and a compendium of metazoan target sets. , 2008, Genome research.

[34]  G. Martin,et al.  A Cre transgene active in developing endodermal organs, heart, limb, and extra‐ocular muscle , 2008, Genesis.

[35]  Jane Lee,et al.  The novel PIAS-like protein hZimp10 is a transcriptional co-activator of the p53 tumor suppressor , 2007, Nucleic acids research.

[36]  A. Flesken-Nikitin,et al.  Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts. , 2007, Cancer research.

[37]  David C. Corney,et al.  Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. , 2006, Cancer research.

[38]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[39]  T. Ratliff.  Molecular Determinants of Resistance to Antiandrogen Therapy , 2004 .

[40]  C. Heinlein,et al.  Androgen receptor in prostate cancer. , 2004, Endocrine reviews.

[41]  P. Nelson,et al.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.

[42]  John D. Storey.  A direct approach to false discovery rates , 2002 .

[43]  C. Huggins,et al.  Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. , 2002, The Journal of urology.

[44]  J Isola,et al.  Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. , 1997, Cancer research.

[45]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[46]  E. Gelmann,et al.  p53 oncogene mutations in human prostate cancer specimens. , 1994, The Journal of urology.

[47]  S. Hilsenbeck,et al.  p53 is mutated in a subset of advanced-stage prostate cancers. , 1993, Cancer research.

[48]  N. Kyprianou,et al.  Activation of programmed cell death in the rat ventral prostate after castration. , 1988, Endocrinology.

[49]  J. Mesirov,et al.  The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.

[50]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[51]  P. Kleihues,et al.  Tumors associated with p53 germline mutations: a synopsis of 91 families. , 1997, The American journal of pathology.